BPC-157 and TB-500 get grouped together as "the healing peptides," which hides how different they actually are. BPC-157 is a 15-amino-acid fragment of a gastric protein dosed in micrograms every day. TB-500 is a synthetic fragment of thymosin beta-4 dosed in milligrams once or twice a week. Confusing the two leads to dosing errors of roughly tenfold.
Quick Comparison Table
- Origin: BPC-157 is derived from body protection compound found in human gastric juice. TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid actin-binding protein.
- Size: BPC-157 is 15 amino acids. Thymosin beta-4 is 43 amino acids, and TB-500 is a shorter active fragment of it.
- Typical dose: BPC-157 runs 250 to 500 mcg per day. TB-500 runs 2 to 2.5 mg per injection.
- Frequency: BPC-157 is once or twice daily. TB-500 is twice weekly during loading, then weekly or biweekly for maintenance.
- Half-life: BPC-157 is short, roughly 4 hours in circulation. Thymosin beta-4 clears more slowly, which is why weekly dosing is workable.
- Primary reported effect: BPC-157 favors localized tendon, ligament, and gut tissue repair. TB-500 favors systemic cell migration, angiogenesis, and flexibility.
How BPC-157 Works
BPC-157 is a pentadecapeptide sequence isolated from a protective compound in gastric juice. The rodent literature associates it with upregulated growth hormone receptor expression in tendon fibroblasts, increased VEGF-driven angiogenesis at the injury site, and modulation of the nitric oxide system. In practical terms, the research signal is strongest for connective tissue and gastrointestinal healing.
The short half-life is the reason for daily dosing. A 250 mcg dose does not sit in circulation for long, so protocols split the daily total into one or two injections, often placed subcutaneously near the injury site. BPC-157 is also unusual among peptides in that it shows activity when given orally in animal models, though injectable protocols remain far more common.
How TB-500 Works
Thymosin beta-4 is the main actin-sequestering protein in mammalian cells. By binding G-actin and regulating filament polymerization, it influences cell migration, which is the rate-limiting step in wound closure. Published work links thymosin beta-4 to accelerated dermal wound healing, angiogenesis, hair follicle activity, and corneal repair, including a randomized phase 2 trial in severe dry eye.
TB-500 is the fragment version sold in research-peptide channels. Because thymosin beta-4 acts systemically rather than only at the injection site, injection location matters less than it does with BPC-157, and the dosing cadence is weekly rather than daily.
Dosing and Reconstitution Math
Both peptides are commonly sold in 5 mg vials, but the sensible BAC water volume differs because the dose sizes differ by an order of magnitude.
- BPC-157, 5 mg vial plus 2 mL BAC water gives 2.5 mg/mL. A 250 mcg dose is 0.1 mL, which is 10 units on a U100 insulin syringe. A 500 mcg dose is 20 units.
- TB-500, 5 mg vial plus 2 mL BAC water gives 2.5 mg/mL, so a 2.5 mg dose is a full 1 mL, which will not fit a 0.5 mL syringe.
- TB-500, 5 mg vial plus 1 mL BAC water gives 5 mg/mL, so a 2.5 mg dose is 0.5 mL, which is 50 units and fits a standard 0.5 mL insulin syringe in one draw.
- If you prefer to keep both vials at the same concentration for simplicity, use 2 mL in each and split the TB-500 dose across two injections.
Rather than working this out by hand each time, enter your vial size, BAC water volume, and target dose into the PeptiTools reconstitution calculator and read the unit count directly off the syringe diagram.
Typical Protocol Shapes
The two peptides run on structurally different schedules, which is what makes them easy to combine without stacking injections on the same clock.
- BPC-157: 250 to 500 mcg per day, subcutaneous, for 4 to 12 weeks, often placed near the target tissue.
- TB-500 loading: 2 to 2.5 mg twice per week for 4 to 6 weeks, subcutaneous or intramuscular.
- TB-500 maintenance: 2 to 2.5 mg once per week or every other week after the loading phase.
- Combined: daily BPC-157 running continuously with TB-500 dosed on two fixed days per week, for example Monday and Thursday.
Stacking the Two
The common rationale for stacking is that the mechanisms are complementary rather than redundant. BPC-157 is associated with local angiogenesis and fibroblast activity at the injury site, while TB-500 is associated with systemic cell migration and reduced adhesion formation. There is no controlled human trial of the combination, so the stack rests on mechanism and anecdote rather than trial data.
If you do stack, keep the vials separate and draw separate injections rather than mixing them in one syringe. Different concentrations, different volumes, and different injection cadences all argue against premixing, and mixing removes your ability to stop one compound and keep the other.
Regulatory and Safety Context
Neither compound is FDA approved. BPC-157 was placed on the FDA bulk drug substances category 2 list in 2023, restricting compounding pharmacy use, and both peptides are prohibited in competition and out of competition under the World Anti-Doping Agency S0 category for non-approved substances. Recent systematic reviews of BPC-157 in orthopedic sports medicine note that essentially all efficacy data is preclinical.
Practical handling risks are the same for both: use bacteriostatic water rather than sterile water, refrigerate after reconstitution, respect the roughly 28-day usable window, and discard any vial that turns cloudy or shows particulates.